Below are the most recent publications written about "Economics, Pharmaceutical" by people in Profiles.
-
Tapper EB, Chhatwal J. We are Not Meeting the Needs of Pharmacoeconomic Models of Nonalcoholic Steatohepatitis, But We Can. Pharmacoeconomics. 2020 05; 38(5):427-429.
-
Wylegala A, Paluch M, Orzechowska-Wylegala B, Galicka-Brzezina A, Chyrek K, Madej A. Pharmacoeconomic analysis of antibiotic therapy in surgical site infections?. Int J Clin Pharmacol Ther. 2019 Sep; 57(9):429-436.
-
Lee M, França UL, Graham RJ, McManus ML. Pre-Nusinersen Hospitalization Costs of Children With Spinal Muscular Atrophy. Pediatr Neurol. 2019 03; 92:3-5.
-
Robinson JC, Howell S, Pearson SD. Value-Based Pricing and Patient Access for Specialty Drugs. JAMA. 2018 Jun 05; 319(21):2169-2170.
-
Garrison LP, Neumann PJ, Willke RJ, Basu A, Danzon PM, Doshi JA, Drummond MF, Lakdawalla DN, Pauly MV, Phelps CE, Ramsey SD, Towse A, Weinstein MC. A Health Economics Approach to US Value Assessment Frameworks-Summary and Recommendations of the ISPOR Special Task Force Report [7]. Value Health. 2018 02; 21(2):161-165.
-
Ferrario A, Araja D, Bochenek T, Catic T, Dankó D, Dimitrova M, Fürst J, Greiciute-Kuprijanov I, Hoxha I, Jakupi A, Laidmäe E, Löblová O, Mardare I, Markovic-Pekovic V, Meshkov D, Novakovic T, Petrova G, Pomorski M, Tomek D, Voncina L, Haycox A, Kanavos P, Vella Bonanno P, Godman B. The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications. Pharmacoeconomics. 2017 Dec; 35(12):1271-1285.
-
McCullagh L, Schmitz S, Barry M, Walsh C. Examining the Feasibility and Utility of Estimating Partial Expected Value of Perfect Information (via a Nonparametric Approach) as Part of the Reimbursement Decision-Making Process in Ireland: Application to Drugs for Cancer. Pharmacoeconomics. 2017 Nov; 35(11):1177-1185.
-
Novakovic T, Martin AP, Parker M, Ferrario A, Vukovic S, Landa K, Duba J, Dankó D, Kotsopoulos N, Godman B, Ristic J, Stefanovic D, Tesic D. The value of innovation in decision-making in health care in Central Eastern Europe - The Sixth International Conference, 2 June 2017, Belgrade, Serbia. Expert Rev Pharmacoecon Outcomes Res. 2017 Dec; 17(6):519-521.
-
Berger ML, Sox H, Willke RJ, Brixner DL, Eichler HG, Goettsch W, Madigan D, Makady A, Schneeweiss S, Tarricone R, Wang SV, Watkins J, Daniel Mullins C. Good practices for real-world data studies of treatment and/or comparative effectiveness: Recommendations from the joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making. Pharmacoepidemiol Drug Saf. 2017 Sep; 26(9):1033-1039.
-
Seeley E, Kesselheim AS. Outcomes-Based Pharmaceutical Contracts: An Answer to High U.S. Drug Spending? Issue Brief (Commonw Fund). 2017 09; 2017:1-8.